Breaking News
March 22, 2018 - ENDO: Big Breakfast May Help in Diabetics
March 22, 2018 - I’m not overweight, so why do I need to eat healthy foods?
March 22, 2018 - UCLA-led study suggests unexpected reason for reduction in cardiovascular health disparities
March 22, 2018 - Study suggests detailed neuropsychological assessment for brief cardiac arrest survivors
March 22, 2018 - Anticoagulant drugs found safe to use in patients undergoing surgery for irregular heartbeat
March 22, 2018 - SP Industries appoints Brian Larkin as new President and CEO
March 22, 2018 - GTx Announced New Data Demonstrating Enobosarm’s Potential to Treat Stress Urinary Incontinence
March 22, 2018 - Higher Risk of Brain Deficits in Older Alcoholics
March 22, 2018 - Top US health official resigns in conflict of interest
March 22, 2018 - Study shows benefits of hair loss drug in improving cognitive function and vascular health
March 22, 2018 - Researchers explain link between 2 key Alzheimer’s proteins
March 22, 2018 - Patients on replacement therapy with thyroid hormone may have more comorbidities
March 22, 2018 - Higher online patient ratings linked to urologists who saw fewer Medicare patients
March 22, 2018 - FDA Approves Ilumya (tildrakizumab-asmn) for the Treatment of Moderate-to-Severe Plaque Psoriasis
March 22, 2018 - Beer Raises Heart Rate; KardiaBand Hyperkalemia Test; CHD Clinics
March 22, 2018 - A retinal implant that is more effective against blindness
March 22, 2018 - New system based on artificial intelligence provides reliable detection of breast cancer
March 22, 2018 - Research offers new understanding about cause of Parkinson’s disease
March 22, 2018 - HORIBA’s Microsemi CRP analyzer improves quality of care in emergency pediatric units, study shows
March 22, 2018 - Neuroscientists move closer to developing tools for deciphering brain function
March 22, 2018 - New test methods with less fear
March 22, 2018 - Range of Vaginal Dryness Products Can Help Postmenopausal Women: Study
March 22, 2018 - Higher Dose Tx Deemed Safe in Pulmonary TB
March 22, 2018 - Discovery of new ALS gene points to cytoskeleton as potential target for drug development
March 22, 2018 - Diet soda associated with higher odds of diabetic retinopathy
March 22, 2018 - LSD reduces ‘sense of self’
March 22, 2018 - Vitamin D deficiency linked to metabolic syndrome in postmenopausal women
March 22, 2018 - Changes in the intestines may be responsible for reversal of diabetes after bariatric surgery
March 22, 2018 - iPads and Cancer; Clot Retrieval and Stroke: It’s PodMed Double T!
March 22, 2018 - Premature births linked to changes in mother’s bacteria
March 22, 2018 - Brain SPECT scans predict treatment outcomes in patients with depression
March 21, 2018 - Researchers succeed in integrating artificial organelles into cells of living organism
March 21, 2018 - Researchers discover ‘missing mutation’ in severe infant epilepsy
March 21, 2018 - Researchers develop statistics-based computational scheme to zoom in on brain function
March 21, 2018 - Verge joins Genomics England’s Discovery Forum industry partnership
March 21, 2018 - Trovagene Announces First Patient Successfully Completes Cycle 1 of Treatment with PCM-075 in Combination with Low Dose Cytarabine (LDAC) in AML Trial
March 21, 2018 - Congenital Cardiac Cath Tx Often Strays from Guidelines
March 21, 2018 - Marked increase in cardiovascular risk factors in women after preeclampsia
March 21, 2018 - New app may help predict, track manic and depressive episodes in bipolar patients
March 21, 2018 - Discovery of genes could lead to development of novel therapies for EBV-related cancers
March 21, 2018 - High-fat, high-cholesterol diet depletes ranks of artery-protecting immune cells
March 21, 2018 - Research misconduct allegations shadow likely CDC appointee
March 21, 2018 - Most Breast Ca Patients Fail to Get Genetic Counseling
March 21, 2018 - Lopsided ear function can lead to lopsided brain development
March 21, 2018 - Acupuncture helps manage menopausal symptoms, review finds
March 21, 2018 - Motor skill training may contribute to reading skills in obese children
March 21, 2018 - Poor dental health may be related to increased diabetes risk
March 21, 2018 - Chronic opioid users at increased risk of complications after spinal fusion surgery
March 21, 2018 - Study uncovers potential therapeutic target against large family of parasites
March 21, 2018 - NSAID use linked to increased risk of atrial fibrillation
March 21, 2018 - Scientists develop brain “stethoscope” that can detect silent seizures
March 21, 2018 - New method predicts effects of global warming on disease
March 21, 2018 - Insurance Company Hurdles Burden Doctors, May Harm Patients
March 21, 2018 - Renal Transplant from HCV-Positive Donors Feasible
March 21, 2018 - Myelodysplastic syndrome: MedlinePlus Medical Encyclopedia
March 21, 2018 - Research reveals brain mechanism involved in language learning
March 21, 2018 - Many parents still hesitate to try early peanut introduction, survey finds
March 21, 2018 - Audiologist urges tinnitus sufferers facing ‘revolving door healthcare’ to seek support
March 21, 2018 - Study reveals impact of prostate cancer on wives and partners of sufferers
March 21, 2018 - ‘Almost a Miracle Drug’: What We Heard This Week
March 21, 2018 - Study shows NIH spent >$100 billion on basic science for new medicines
March 21, 2018 - Columbia researchers identify nerve cells that drive fruit fly’s escape behavior
March 21, 2018 - Sartorius Stedim Biotech selected by ABL Europe to supply single-use process technologies
March 21, 2018 - Increase in coffee consumption may help battle against colon cancer
March 21, 2018 - Hydrogel may accelerate healing of diabetic ulcers
March 21, 2018 - Dermira’s Two Phase 3 Trials Evaluating Olumacostat Glasaretil in Patients with Acne Vulgaris Did Not Meet Co-Primary Endpoints
March 21, 2018 - DePuy Synthes introduces ACTIS Total Hip System for improving initial implant stability
March 21, 2018 - ‘Oh, It Was Nothing’
March 21, 2018 - Herbal drug kratom linked to salmonella illnesses, CDC says
March 21, 2018 - New optical point-of-care device could enhance screening for thyroid nodules
March 21, 2018 - FDA Expands Approval of Adcetris (brentuximab vedotin) for First-Line Treatment of Stage III or IV Classical Hodgkin Lymphoma in Combination with Chemotherapy
March 21, 2018 - Eosinophilic Esophagitis: Late Manifestation of Allergic March
March 21, 2018 - Signaling pathway involving the Golgi apparatus identified in cells with Huntington’s disease
March 21, 2018 - Quintupling inhaled steroid doses may not benefit children with asthma
March 21, 2018 - Study shows clear connection between cardiovascular fitness in middle age and dementia risk
March 21, 2018 - Premature babies have higher risks of health complications in Bangladesh
March 21, 2018 - Child’s temperament and parenting influence weight gain in babies
March 21, 2018 - Researchers find the heart to be capable of arrhythmia termination after local gene therapy
March 21, 2018 - Inhealthcare to provide digital infrastructure for NHS to help protect people from falls
March 21, 2018 - Flu Season Finally Slowing Down
Therapy Order Affects Survival in Metastatic CRC

Therapy Order Affects Survival in Metastatic CRC

image_pdfDownload PDFimage_print

Action Points

  • Note that this study was published as an abstract and presented at a conference. These data and conclusions should be considered to be preliminary until published in a peer-reviewed journal.

SAN FRANCISCO — A strategy that had minimal impact on chemotherapy success made a significant difference in targeted therapies’ impact on colorectal cancer survival, according to a small randomized study.

Giving regorafenib (Stivarga) before cetuximab (Erbitux) resulted in a median overall survival (OS) of 17.4 months as compared with 11.6 months when cetuximab preceded regorafenib. Moreover, finishing treatment with cetuximab resulted in a more prolonged second progression-free interval (PFS2), whereas PFS1 did not differ significantly according to the drug sequence, reported Kohei Shitara, MD, of the National Cancer Center Hospital East in Kashiwa in Japan, and colleagues.

A subgroup analysis showed a consistent advantage in favor of regorafenib followed by cetuximab, including almost a 9-month difference among patients with left-sided tumors, they reported here at the Gastrointestinal Cancers Symposium.

“The safety and quality of life were comparable between the two arms, and but was generally lower during regorafenib treatment,” said Shitara. “There were no unexpected adverse-event signals. A biomarker analysis is still ongoing.”

Shitara noted that the results apply only to patients with RAS/BRAF wild type tumors.

Though preliminary, the findings suggest that lessons learned from sequencing studies of chemotherapy may not apply in the era of targeted therapies, said Michael J. Hall, MD, of Fox Chase Cancer Center in Philadelphia.

“Back into the 1990s and into the 2000s, we spent a lot of time doing sequence studies with chemotherapy, and sometimes it mattered and sometimes it didn’t,” Hall told MedPage Today. “It never really mattered to the degree that they showed in this study. This was a huge difference.”

“The findings started me thinking about whether the cetuximab might have caused mutations in the tumor that were worse later on for the therapies that followed. With more molecularly targeted therapies now, do we need to think more about a sequence? If we’re inducing these mutations that are going to drive the tumors in bad ways, we might not want to do that,” added Hall, who was not involved in the study.

Both regorafenib and cetuximab have indications for treating metastatic colorectal cancer. Both agents are members of the EGFR-inhibitor class, and the optimal sequence for EGFR-targeted therapies has yet to be determined, Shitara noted.

Investigators at 29 centers in Japan enrolled patients in a phase II randomized trial to evaluate regorafenib followed by cetuximab — or the reverse sequence — in patients with RAS/BRAF wild-type metastatic colorectal cancer. Treatment with the initial drug continued until disease progression, at which time patients switched to the second drug drug in the sequence.

All patients had previously received combination therapy with a fluoropyrimidine, oxaliplatin, and irinotecan. Investigators had the option to give cetuximab with or without irinotecan.

The trial had a primary endpoint of OS. Key secondary endpoints included PFS1, PFS2, safety, and quality of life. Serial biomarker analyses, including oncogenic alterations in circulating tumor DNA and various serum proteins, were an exploratory endpoint of the trial.

The trial had an accrual target of 180 patients, but enrollment ended because of slow accrual after 101 patients had been randomized and treated.

The results showed a 5.8-month difference in survival for patients who initiated treatment with regorafenib. The difference represented a 39% reduction in the survival hazard in favor of the regorafenib-first sequence (95% CI 0.39-0.96, P=0.029).

Analysis of secondary endpoints showed a median PFS1 of 2.4 months for patients who received regorafenib first and 4.2 months for those who began treatment with cetuximab, which did not achieve statistical significance (HR 0.97, 95% CI 0.82-1.54, P=0.91). In contrast, median PFS2 was significantly longer with the regorafenib-first sequence (5.2 versus 1.8 months, HR 0.29, 95% CI 0.17-0.50, P<0.0001).

Subgroup analysis did not identify patient groups that appeared to benefit more from starting with cetuximab. Shitara said that 81 of the 101 patients had left-sided primary tumors. In that subgroup, patients who started treatment with regorafenib had a median OS of 20.5 months compared with 11.9 months for those who received cetuximab first. The difference represented a 49% reduction in the hazard ratio (95% CI 0.30-0.86, P=0.011).

The study was supported by Bayer Yakuhin.

Shitara disclosed relevant relationships with AbbVie, Novartis, Ono Pharmaceutical, Yakult, Astellas, Bristol-Myers Squibb, Lilly, Pfizer, Takeda, Chugai Pharma, Daiichi Sankyo, Dainippon Sumitomo Pharma, Merck Sharp and Dohme, and Taiho Pharmaceutical.


last updated

Tagged with:

About author

Related Articles